NMT1 and breast carcinoma: Proteome samples were generated from MDA-MB-231 breast cancer cells treated with a potent and specific NMT inhibitor (IMP-1088, structure in Fig. 2) (2) to generate free N-terminal Gly residues at sites of N-myristoylation, before lysing with SrtA reaction buffer.